instruction
stringlengths 39
316
| response
stringlengths 121
336
| text
stringlengths 194
685
|
|---|---|---|
Can you tell me the median PFS for Panobinostat+Bortezomib+Dexamethasone (Pano-Vd)? | Patients treated with the Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) have a median Progression-Free Survival (PFS) rate of 11.99 months, with a 95% CI of (10.33, 12.94). | ### Instruction: Can you tell me the median PFS for Panobinostat+Bortezomib+Dexamethasone (Pano-Vd)?
### Response: Patients treated with the Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) have a median Progression-Free Survival (PFS) rate of 11.99 months, with a 95% CI of (10.33, 12.94). |
What’s the median PFS associated with Panobinostat+Bortezomib+Dexamethasone (Pano-Vd)? | Patients treated with the Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) have a median Progression-Free Survival (PFS) rate of 11.99 months, with a 95% CI of (10.33, 12.94). | ### Instruction: What’s the median PFS associated with Panobinostat+Bortezomib+Dexamethasone (Pano-Vd)?
### Response: Patients treated with the Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) have a median Progression-Free Survival (PFS) rate of 11.99 months, with a 95% CI of (10.33, 12.94). |
Could you provide the median PFS of Panobinostat+Bortezomib+Dexamethasone (Pano-Vd)? | Patients treated with the Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) have a median Progression-Free Survival (PFS) rate of 11.99 months, with a 95% CI of (10.33, 12.94). | ### Instruction: Could you provide the median PFS of Panobinostat+Bortezomib+Dexamethasone (Pano-Vd)?
### Response: Patients treated with the Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) have a median Progression-Free Survival (PFS) rate of 11.99 months, with a 95% CI of (10.33, 12.94). |
I’d like to know the median PFS of Panobinostat+Bortezomib+Dexamethasone (Pano-Vd). | Patients treated with the Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) have a median Progression-Free Survival (PFS) rate of 11.99 months, with a 95% CI of (10.33, 12.94). | ### Instruction: I’d like to know the median PFS of Panobinostat+Bortezomib+Dexamethasone (Pano-Vd).
### Response: Patients treated with the Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) have a median Progression-Free Survival (PFS) rate of 11.99 months, with a 95% CI of (10.33, 12.94). |
Do you have information on the median PFS of Panobinostat+Bortezomib+Dexamethasone (Pano-Vd)? | Patients treated with the Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) have a median Progression-Free Survival (PFS) rate of 11.99 months, with a 95% CI of (10.33, 12.94). | ### Instruction: Do you have information on the median PFS of Panobinostat+Bortezomib+Dexamethasone (Pano-Vd)?
### Response: Patients treated with the Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) have a median Progression-Free Survival (PFS) rate of 11.99 months, with a 95% CI of (10.33, 12.94). |
What is the median progression-free survival (PFS) for Panobinostat+Bortezomib+Dexamethasone (Pano-Vd)? | Patients treated with the Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) have a median Progression-Free Survival (PFS) rate of 11.99 months, with a 95% CI of (10.33, 12.94). | ### Instruction: What is the median progression-free survival (PFS) for Panobinostat+Bortezomib+Dexamethasone (Pano-Vd)?
### Response: Patients treated with the Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) have a median Progression-Free Survival (PFS) rate of 11.99 months, with a 95% CI of (10.33, 12.94). |
Can you inform me about the median PFS for Panobinostat+Bortezomib+Dexamethasone (Pano-Vd)? | Patients treated with the Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) have a median Progression-Free Survival (PFS) rate of 11.99 months, with a 95% CI of (10.33, 12.94). | ### Instruction: Can you inform me about the median PFS for Panobinostat+Bortezomib+Dexamethasone (Pano-Vd)?
### Response: Patients treated with the Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) have a median Progression-Free Survival (PFS) rate of 11.99 months, with a 95% CI of (10.33, 12.94). |
I’m interested in the median PFS of Panobinostat+Bortezomib+Dexamethasone (Pano-Vd). | Patients treated with the Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) have a median Progression-Free Survival (PFS) rate of 11.99 months, with a 95% CI of (10.33, 12.94). | ### Instruction: I’m interested in the median PFS of Panobinostat+Bortezomib+Dexamethasone (Pano-Vd).
### Response: Patients treated with the Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) have a median Progression-Free Survival (PFS) rate of 11.99 months, with a 95% CI of (10.33, 12.94). |
Could you tell me the median PFS for Panobinostat+Bortezomib+Dexamethasone (Pano-Vd)? | Patients treated with the Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) have a median Progression-Free Survival (PFS) rate of 11.99 months, with a 95% CI of (10.33, 12.94). | ### Instruction: Could you tell me the median PFS for Panobinostat+Bortezomib+Dexamethasone (Pano-Vd)?
### Response: Patients treated with the Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) have a median Progression-Free Survival (PFS) rate of 11.99 months, with a 95% CI of (10.33, 12.94). |
What is the median PFS rate for Panobinostat+Bortezomib+Dexamethasone (Pano-Vd)? | Patients treated with the Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) have a median Progression-Free Survival (PFS) rate of 11.99 months, with a 95% CI of (10.33, 12.94). | ### Instruction: What is the median PFS rate for Panobinostat+Bortezomib+Dexamethasone (Pano-Vd)?
### Response: Patients treated with the Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) have a median Progression-Free Survival (PFS) rate of 11.99 months, with a 95% CI of (10.33, 12.94). |
What is the median Progression-Free Survival (PFS) rate in patients treated with Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) regimen? | Patients treated with the Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) have a median Progression-Free Survival (PFS) rate of 11.99 months, with a 95% CI of (10.33, 12.94). | ### Instruction: What is the median Progression-Free Survival (PFS) rate in patients treated with Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) regimen?
### Response: Patients treated with the Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) have a median Progression-Free Survival (PFS) rate of 11.99 months, with a 95% CI of (10.33, 12.94). |
What is the median PFS rate in patients who have undergone Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) regimen? | Patients treated with the Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) have a median Progression-Free Survival (PFS) rate of 11.99 months, with a 95% CI of (10.33, 12.94). | ### Instruction: What is the median PFS rate in patients who have undergone Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) regimen?
### Response: Patients treated with the Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) have a median Progression-Free Survival (PFS) rate of 11.99 months, with a 95% CI of (10.33, 12.94). |
Can you tell me the median Progression-Free Survival rate in patients who were treated with Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) regimen? | Patients treated with the Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) have a median Progression-Free Survival (PFS) rate of 11.99 months, with a 95% CI of (10.33, 12.94). | ### Instruction: Can you tell me the median Progression-Free Survival rate in patients who were treated with Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) regimen?
### Response: Patients treated with the Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) have a median Progression-Free Survival (PFS) rate of 11.99 months, with a 95% CI of (10.33, 12.94). |
What’s the median PFS rate for patients receiving Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) regimen? | Patients treated with the Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) have a median Progression-Free Survival (PFS) rate of 11.99 months, with a 95% CI of (10.33, 12.94). | ### Instruction: What’s the median PFS rate for patients receiving Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) regimen?
### Response: Patients treated with the Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) have a median Progression-Free Survival (PFS) rate of 11.99 months, with a 95% CI of (10.33, 12.94). |
Could you provide the median Progression-Free Survival rate for patients treated with Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) regimen? | Patients treated with the Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) have a median Progression-Free Survival (PFS) rate of 11.99 months, with a 95% CI of (10.33, 12.94). | ### Instruction: Could you provide the median Progression-Free Survival rate for patients treated with Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) regimen?
### Response: Patients treated with the Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) have a median Progression-Free Survival (PFS) rate of 11.99 months, with a 95% CI of (10.33, 12.94). |
What is the median rate of Progression-Free Survival in patients who have been treated with Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) regimen? | Patients treated with the Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) have a median Progression-Free Survival (PFS) rate of 11.99 months, with a 95% CI of (10.33, 12.94). | ### Instruction: What is the median rate of Progression-Free Survival in patients who have been treated with Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) regimen?
### Response: Patients treated with the Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) have a median Progression-Free Survival (PFS) rate of 11.99 months, with a 95% CI of (10.33, 12.94). |
Can you inform me about the median PFS rate in patients that were treated with Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) regimen? | Patients treated with the Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) have a median Progression-Free Survival (PFS) rate of 11.99 months, with a 95% CI of (10.33, 12.94). | ### Instruction: Can you inform me about the median PFS rate in patients that were treated with Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) regimen?
### Response: Patients treated with the Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) have a median Progression-Free Survival (PFS) rate of 11.99 months, with a 95% CI of (10.33, 12.94). |
What is the median PFS rate for patients that have undergone Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) regimen? | Patients treated with the Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) have a median Progression-Free Survival (PFS) rate of 11.99 months, with a 95% CI of (10.33, 12.94). | ### Instruction: What is the median PFS rate for patients that have undergone Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) regimen?
### Response: Patients treated with the Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) have a median Progression-Free Survival (PFS) rate of 11.99 months, with a 95% CI of (10.33, 12.94). |
Could you tell me the median Progression-Free Survival rate for patients who received Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) regimen? | Patients treated with the Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) have a median Progression-Free Survival (PFS) rate of 11.99 months, with a 95% CI of (10.33, 12.94). | ### Instruction: Could you tell me the median Progression-Free Survival rate for patients who received Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) regimen?
### Response: Patients treated with the Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) have a median Progression-Free Survival (PFS) rate of 11.99 months, with a 95% CI of (10.33, 12.94). |
What’s the median rate of PFS in patients treated with Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) regimen? | Patients treated with the Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) have a median Progression-Free Survival (PFS) rate of 11.99 months, with a 95% CI of (10.33, 12.94). | ### Instruction: What’s the median rate of PFS in patients treated with Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) regimen?
### Response: Patients treated with the Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) have a median Progression-Free Survival (PFS) rate of 11.99 months, with a 95% CI of (10.33, 12.94). |
Can you share the median Progression-Free Survival rate in patients who have received Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) regimen? | Patients treated with the Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) have a median Progression-Free Survival (PFS) rate of 11.99 months, with a 95% CI of (10.33, 12.94). | ### Instruction: Can you share the median Progression-Free Survival rate in patients who have received Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) regimen?
### Response: Patients treated with the Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) have a median Progression-Free Survival (PFS) rate of 11.99 months, with a 95% CI of (10.33, 12.94). |
Can you tell me the median PFS for Placebo+Bortezomib+Dexamethasone (Vd)? | Patients treated with the Placebo+Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 8.08 months, with a 95% CI of (7.56, 9.23). | ### Instruction: Can you tell me the median PFS for Placebo+Bortezomib+Dexamethasone (Vd)?
### Response: Patients treated with the Placebo+Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 8.08 months, with a 95% CI of (7.56, 9.23). |
What’s the median PFS associated with Placebo+Bortezomib+Dexamethasone (Vd)? | Patients treated with the Placebo+Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 8.08 months, with a 95% CI of (7.56, 9.23). | ### Instruction: What’s the median PFS associated with Placebo+Bortezomib+Dexamethasone (Vd)?
### Response: Patients treated with the Placebo+Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 8.08 months, with a 95% CI of (7.56, 9.23). |
Could you provide the median PFS of Placebo+Bortezomib+Dexamethasone (Vd)? | Patients treated with the Placebo+Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 8.08 months, with a 95% CI of (7.56, 9.23). | ### Instruction: Could you provide the median PFS of Placebo+Bortezomib+Dexamethasone (Vd)?
### Response: Patients treated with the Placebo+Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 8.08 months, with a 95% CI of (7.56, 9.23). |
I’d like to know the median PFS of Placebo+Bortezomib+Dexamethasone (Vd). | Patients treated with the Placebo+Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 8.08 months, with a 95% CI of (7.56, 9.23). | ### Instruction: I’d like to know the median PFS of Placebo+Bortezomib+Dexamethasone (Vd).
### Response: Patients treated with the Placebo+Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 8.08 months, with a 95% CI of (7.56, 9.23). |
Do you have information on the median PFS of Placebo+Bortezomib+Dexamethasone (Vd)? | Patients treated with the Placebo+Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 8.08 months, with a 95% CI of (7.56, 9.23). | ### Instruction: Do you have information on the median PFS of Placebo+Bortezomib+Dexamethasone (Vd)?
### Response: Patients treated with the Placebo+Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 8.08 months, with a 95% CI of (7.56, 9.23). |
What is the median progression-free survival (PFS) for Placebo+Bortezomib+Dexamethasone (Vd)? | Patients treated with the Placebo+Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 8.08 months, with a 95% CI of (7.56, 9.23). | ### Instruction: What is the median progression-free survival (PFS) for Placebo+Bortezomib+Dexamethasone (Vd)?
### Response: Patients treated with the Placebo+Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 8.08 months, with a 95% CI of (7.56, 9.23). |
Can you inform me about the median PFS for Placebo+Bortezomib+Dexamethasone (Vd)? | Patients treated with the Placebo+Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 8.08 months, with a 95% CI of (7.56, 9.23). | ### Instruction: Can you inform me about the median PFS for Placebo+Bortezomib+Dexamethasone (Vd)?
### Response: Patients treated with the Placebo+Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 8.08 months, with a 95% CI of (7.56, 9.23). |
I’m interested in the median PFS of Placebo+Bortezomib+Dexamethasone (Vd). | Patients treated with the Placebo+Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 8.08 months, with a 95% CI of (7.56, 9.23). | ### Instruction: I’m interested in the median PFS of Placebo+Bortezomib+Dexamethasone (Vd).
### Response: Patients treated with the Placebo+Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 8.08 months, with a 95% CI of (7.56, 9.23). |
Could you tell me the median PFS for Placebo+Bortezomib+Dexamethasone (Vd)? | Patients treated with the Placebo+Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 8.08 months, with a 95% CI of (7.56, 9.23). | ### Instruction: Could you tell me the median PFS for Placebo+Bortezomib+Dexamethasone (Vd)?
### Response: Patients treated with the Placebo+Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 8.08 months, with a 95% CI of (7.56, 9.23). |
What is the median PFS rate for Placebo+Bortezomib+Dexamethasone (Vd)? | Patients treated with the Placebo+Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 8.08 months, with a 95% CI of (7.56, 9.23). | ### Instruction: What is the median PFS rate for Placebo+Bortezomib+Dexamethasone (Vd)?
### Response: Patients treated with the Placebo+Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 8.08 months, with a 95% CI of (7.56, 9.23). |
What is the median Progression-Free Survival (PFS) rate in patients treated with Placebo+Bortezomib+Dexamethasone (Vd) regimen? | Patients treated with the Placebo+Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 8.08 months, with a 95% CI of (7.56, 9.23). | ### Instruction: What is the median Progression-Free Survival (PFS) rate in patients treated with Placebo+Bortezomib+Dexamethasone (Vd) regimen?
### Response: Patients treated with the Placebo+Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 8.08 months, with a 95% CI of (7.56, 9.23). |
What is the median PFS rate in patients who have undergone Placebo+Bortezomib+Dexamethasone (Vd) regimen? | Patients treated with the Placebo+Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 8.08 months, with a 95% CI of (7.56, 9.23). | ### Instruction: What is the median PFS rate in patients who have undergone Placebo+Bortezomib+Dexamethasone (Vd) regimen?
### Response: Patients treated with the Placebo+Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 8.08 months, with a 95% CI of (7.56, 9.23). |
Can you tell me the median Progression-Free Survival rate in patients who were treated with Placebo+Bortezomib+Dexamethasone (Vd) regimen? | Patients treated with the Placebo+Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 8.08 months, with a 95% CI of (7.56, 9.23). | ### Instruction: Can you tell me the median Progression-Free Survival rate in patients who were treated with Placebo+Bortezomib+Dexamethasone (Vd) regimen?
### Response: Patients treated with the Placebo+Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 8.08 months, with a 95% CI of (7.56, 9.23). |
What’s the median PFS rate for patients receiving Placebo+Bortezomib+Dexamethasone (Vd) regimen? | Patients treated with the Placebo+Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 8.08 months, with a 95% CI of (7.56, 9.23). | ### Instruction: What’s the median PFS rate for patients receiving Placebo+Bortezomib+Dexamethasone (Vd) regimen?
### Response: Patients treated with the Placebo+Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 8.08 months, with a 95% CI of (7.56, 9.23). |
Could you provide the median Progression-Free Survival rate for patients treated with Placebo+Bortezomib+Dexamethasone (Vd) regimen? | Patients treated with the Placebo+Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 8.08 months, with a 95% CI of (7.56, 9.23). | ### Instruction: Could you provide the median Progression-Free Survival rate for patients treated with Placebo+Bortezomib+Dexamethasone (Vd) regimen?
### Response: Patients treated with the Placebo+Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 8.08 months, with a 95% CI of (7.56, 9.23). |
What is the median rate of Progression-Free Survival in patients who have been treated with Placebo+Bortezomib+Dexamethasone (Vd) regimen? | Patients treated with the Placebo+Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 8.08 months, with a 95% CI of (7.56, 9.23). | ### Instruction: What is the median rate of Progression-Free Survival in patients who have been treated with Placebo+Bortezomib+Dexamethasone (Vd) regimen?
### Response: Patients treated with the Placebo+Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 8.08 months, with a 95% CI of (7.56, 9.23). |
Can you inform me about the median PFS rate in patients that were treated with Placebo+Bortezomib+Dexamethasone (Vd) regimen? | Patients treated with the Placebo+Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 8.08 months, with a 95% CI of (7.56, 9.23). | ### Instruction: Can you inform me about the median PFS rate in patients that were treated with Placebo+Bortezomib+Dexamethasone (Vd) regimen?
### Response: Patients treated with the Placebo+Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 8.08 months, with a 95% CI of (7.56, 9.23). |
What is the median PFS rate for patients that have undergone Placebo+Bortezomib+Dexamethasone (Vd) regimen? | Patients treated with the Placebo+Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 8.08 months, with a 95% CI of (7.56, 9.23). | ### Instruction: What is the median PFS rate for patients that have undergone Placebo+Bortezomib+Dexamethasone (Vd) regimen?
### Response: Patients treated with the Placebo+Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 8.08 months, with a 95% CI of (7.56, 9.23). |
Could you tell me the median Progression-Free Survival rate for patients who received Placebo+Bortezomib+Dexamethasone (Vd) regimen? | Patients treated with the Placebo+Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 8.08 months, with a 95% CI of (7.56, 9.23). | ### Instruction: Could you tell me the median Progression-Free Survival rate for patients who received Placebo+Bortezomib+Dexamethasone (Vd) regimen?
### Response: Patients treated with the Placebo+Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 8.08 months, with a 95% CI of (7.56, 9.23). |
What’s the median rate of PFS in patients treated with Placebo+Bortezomib+Dexamethasone (Vd) regimen? | Patients treated with the Placebo+Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 8.08 months, with a 95% CI of (7.56, 9.23). | ### Instruction: What’s the median rate of PFS in patients treated with Placebo+Bortezomib+Dexamethasone (Vd) regimen?
### Response: Patients treated with the Placebo+Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 8.08 months, with a 95% CI of (7.56, 9.23). |
Can you share the median Progression-Free Survival rate in patients who have received Placebo+Bortezomib+Dexamethasone (Vd) regimen? | Patients treated with the Placebo+Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 8.08 months, with a 95% CI of (7.56, 9.23). | ### Instruction: Can you share the median Progression-Free Survival rate in patients who have received Placebo+Bortezomib+Dexamethasone (Vd) regimen?
### Response: Patients treated with the Placebo+Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 8.08 months, with a 95% CI of (7.56, 9.23). |
Can you tell me the median PFS for Dexamethasone+Lenalidomide+Carfilzomib (KRd)? | Patients treated with the Dexamethasone+Lenalidomide+Carfilzomib (KRd) have a median Progression-Free Survival (PFS) rate of 26.1 months, with a 95% CI of (23.2, 30.3). | ### Instruction: Can you tell me the median PFS for Dexamethasone+Lenalidomide+Carfilzomib (KRd)?
### Response: Patients treated with the Dexamethasone+Lenalidomide+Carfilzomib (KRd) have a median Progression-Free Survival (PFS) rate of 26.1 months, with a 95% CI of (23.2, 30.3). |
What’s the median PFS associated with Dexamethasone+Lenalidomide+Carfilzomib (KRd)? | Patients treated with the Dexamethasone+Lenalidomide+Carfilzomib (KRd) have a median Progression-Free Survival (PFS) rate of 26.1 months, with a 95% CI of (23.2, 30.3). | ### Instruction: What’s the median PFS associated with Dexamethasone+Lenalidomide+Carfilzomib (KRd)?
### Response: Patients treated with the Dexamethasone+Lenalidomide+Carfilzomib (KRd) have a median Progression-Free Survival (PFS) rate of 26.1 months, with a 95% CI of (23.2, 30.3). |
Could you provide the median PFS of Dexamethasone+Lenalidomide+Carfilzomib (KRd)? | Patients treated with the Dexamethasone+Lenalidomide+Carfilzomib (KRd) have a median Progression-Free Survival (PFS) rate of 26.1 months, with a 95% CI of (23.2, 30.3). | ### Instruction: Could you provide the median PFS of Dexamethasone+Lenalidomide+Carfilzomib (KRd)?
### Response: Patients treated with the Dexamethasone+Lenalidomide+Carfilzomib (KRd) have a median Progression-Free Survival (PFS) rate of 26.1 months, with a 95% CI of (23.2, 30.3). |
I’d like to know the median PFS of Dexamethasone+Lenalidomide+Carfilzomib (KRd). | Patients treated with the Dexamethasone+Lenalidomide+Carfilzomib (KRd) have a median Progression-Free Survival (PFS) rate of 26.1 months, with a 95% CI of (23.2, 30.3). | ### Instruction: I’d like to know the median PFS of Dexamethasone+Lenalidomide+Carfilzomib (KRd).
### Response: Patients treated with the Dexamethasone+Lenalidomide+Carfilzomib (KRd) have a median Progression-Free Survival (PFS) rate of 26.1 months, with a 95% CI of (23.2, 30.3). |
Do you have information on the median PFS of Dexamethasone+Lenalidomide+Carfilzomib (KRd)? | Patients treated with the Dexamethasone+Lenalidomide+Carfilzomib (KRd) have a median Progression-Free Survival (PFS) rate of 26.1 months, with a 95% CI of (23.2, 30.3). | ### Instruction: Do you have information on the median PFS of Dexamethasone+Lenalidomide+Carfilzomib (KRd)?
### Response: Patients treated with the Dexamethasone+Lenalidomide+Carfilzomib (KRd) have a median Progression-Free Survival (PFS) rate of 26.1 months, with a 95% CI of (23.2, 30.3). |
What is the median progression-free survival (PFS) for Dexamethasone+Lenalidomide+Carfilzomib (KRd)? | Patients treated with the Dexamethasone+Lenalidomide+Carfilzomib (KRd) have a median Progression-Free Survival (PFS) rate of 26.1 months, with a 95% CI of (23.2, 30.3). | ### Instruction: What is the median progression-free survival (PFS) for Dexamethasone+Lenalidomide+Carfilzomib (KRd)?
### Response: Patients treated with the Dexamethasone+Lenalidomide+Carfilzomib (KRd) have a median Progression-Free Survival (PFS) rate of 26.1 months, with a 95% CI of (23.2, 30.3). |
Can you inform me about the median PFS for Dexamethasone+Lenalidomide+Carfilzomib (KRd)? | Patients treated with the Dexamethasone+Lenalidomide+Carfilzomib (KRd) have a median Progression-Free Survival (PFS) rate of 26.1 months, with a 95% CI of (23.2, 30.3). | ### Instruction: Can you inform me about the median PFS for Dexamethasone+Lenalidomide+Carfilzomib (KRd)?
### Response: Patients treated with the Dexamethasone+Lenalidomide+Carfilzomib (KRd) have a median Progression-Free Survival (PFS) rate of 26.1 months, with a 95% CI of (23.2, 30.3). |
I’m interested in the median PFS of Dexamethasone+Lenalidomide+Carfilzomib (KRd). | Patients treated with the Dexamethasone+Lenalidomide+Carfilzomib (KRd) have a median Progression-Free Survival (PFS) rate of 26.1 months, with a 95% CI of (23.2, 30.3). | ### Instruction: I’m interested in the median PFS of Dexamethasone+Lenalidomide+Carfilzomib (KRd).
### Response: Patients treated with the Dexamethasone+Lenalidomide+Carfilzomib (KRd) have a median Progression-Free Survival (PFS) rate of 26.1 months, with a 95% CI of (23.2, 30.3). |
Could you tell me the median PFS for Dexamethasone+Lenalidomide+Carfilzomib (KRd)? | Patients treated with the Dexamethasone+Lenalidomide+Carfilzomib (KRd) have a median Progression-Free Survival (PFS) rate of 26.1 months, with a 95% CI of (23.2, 30.3). | ### Instruction: Could you tell me the median PFS for Dexamethasone+Lenalidomide+Carfilzomib (KRd)?
### Response: Patients treated with the Dexamethasone+Lenalidomide+Carfilzomib (KRd) have a median Progression-Free Survival (PFS) rate of 26.1 months, with a 95% CI of (23.2, 30.3). |
What is the median PFS rate for Dexamethasone+Lenalidomide+Carfilzomib (KRd)? | Patients treated with the Dexamethasone+Lenalidomide+Carfilzomib (KRd) have a median Progression-Free Survival (PFS) rate of 26.1 months, with a 95% CI of (23.2, 30.3). | ### Instruction: What is the median PFS rate for Dexamethasone+Lenalidomide+Carfilzomib (KRd)?
### Response: Patients treated with the Dexamethasone+Lenalidomide+Carfilzomib (KRd) have a median Progression-Free Survival (PFS) rate of 26.1 months, with a 95% CI of (23.2, 30.3). |
What is the median Progression-Free Survival (PFS) rate in patients treated with Dexamethasone+Lenalidomide+Carfilzomib (KRd) regimen? | Patients treated with the Dexamethasone+Lenalidomide+Carfilzomib (KRd) have a median Progression-Free Survival (PFS) rate of 26.1 months, with a 95% CI of (23.2, 30.3). | ### Instruction: What is the median Progression-Free Survival (PFS) rate in patients treated with Dexamethasone+Lenalidomide+Carfilzomib (KRd) regimen?
### Response: Patients treated with the Dexamethasone+Lenalidomide+Carfilzomib (KRd) have a median Progression-Free Survival (PFS) rate of 26.1 months, with a 95% CI of (23.2, 30.3). |
What is the median PFS rate in patients who have undergone Dexamethasone+Lenalidomide+Carfilzomib (KRd) regimen? | Patients treated with the Dexamethasone+Lenalidomide+Carfilzomib (KRd) have a median Progression-Free Survival (PFS) rate of 26.1 months, with a 95% CI of (23.2, 30.3). | ### Instruction: What is the median PFS rate in patients who have undergone Dexamethasone+Lenalidomide+Carfilzomib (KRd) regimen?
### Response: Patients treated with the Dexamethasone+Lenalidomide+Carfilzomib (KRd) have a median Progression-Free Survival (PFS) rate of 26.1 months, with a 95% CI of (23.2, 30.3). |
Can you tell me the median Progression-Free Survival rate in patients who were treated with Dexamethasone+Lenalidomide+Carfilzomib (KRd) regimen? | Patients treated with the Dexamethasone+Lenalidomide+Carfilzomib (KRd) have a median Progression-Free Survival (PFS) rate of 26.1 months, with a 95% CI of (23.2, 30.3). | ### Instruction: Can you tell me the median Progression-Free Survival rate in patients who were treated with Dexamethasone+Lenalidomide+Carfilzomib (KRd) regimen?
### Response: Patients treated with the Dexamethasone+Lenalidomide+Carfilzomib (KRd) have a median Progression-Free Survival (PFS) rate of 26.1 months, with a 95% CI of (23.2, 30.3). |
What’s the median PFS rate for patients receiving Dexamethasone+Lenalidomide+Carfilzomib (KRd) regimen? | Patients treated with the Dexamethasone+Lenalidomide+Carfilzomib (KRd) have a median Progression-Free Survival (PFS) rate of 26.1 months, with a 95% CI of (23.2, 30.3). | ### Instruction: What’s the median PFS rate for patients receiving Dexamethasone+Lenalidomide+Carfilzomib (KRd) regimen?
### Response: Patients treated with the Dexamethasone+Lenalidomide+Carfilzomib (KRd) have a median Progression-Free Survival (PFS) rate of 26.1 months, with a 95% CI of (23.2, 30.3). |
Could you provide the median Progression-Free Survival rate for patients treated with Dexamethasone+Lenalidomide+Carfilzomib (KRd) regimen? | Patients treated with the Dexamethasone+Lenalidomide+Carfilzomib (KRd) have a median Progression-Free Survival (PFS) rate of 26.1 months, with a 95% CI of (23.2, 30.3). | ### Instruction: Could you provide the median Progression-Free Survival rate for patients treated with Dexamethasone+Lenalidomide+Carfilzomib (KRd) regimen?
### Response: Patients treated with the Dexamethasone+Lenalidomide+Carfilzomib (KRd) have a median Progression-Free Survival (PFS) rate of 26.1 months, with a 95% CI of (23.2, 30.3). |
What is the median rate of Progression-Free Survival in patients who have been treated with Dexamethasone+Lenalidomide+Carfilzomib (KRd) regimen? | Patients treated with the Dexamethasone+Lenalidomide+Carfilzomib (KRd) have a median Progression-Free Survival (PFS) rate of 26.1 months, with a 95% CI of (23.2, 30.3). | ### Instruction: What is the median rate of Progression-Free Survival in patients who have been treated with Dexamethasone+Lenalidomide+Carfilzomib (KRd) regimen?
### Response: Patients treated with the Dexamethasone+Lenalidomide+Carfilzomib (KRd) have a median Progression-Free Survival (PFS) rate of 26.1 months, with a 95% CI of (23.2, 30.3). |
Can you inform me about the median PFS rate in patients that were treated with Dexamethasone+Lenalidomide+Carfilzomib (KRd) regimen? | Patients treated with the Dexamethasone+Lenalidomide+Carfilzomib (KRd) have a median Progression-Free Survival (PFS) rate of 26.1 months, with a 95% CI of (23.2, 30.3). | ### Instruction: Can you inform me about the median PFS rate in patients that were treated with Dexamethasone+Lenalidomide+Carfilzomib (KRd) regimen?
### Response: Patients treated with the Dexamethasone+Lenalidomide+Carfilzomib (KRd) have a median Progression-Free Survival (PFS) rate of 26.1 months, with a 95% CI of (23.2, 30.3). |
What is the median PFS rate for patients that have undergone Dexamethasone+Lenalidomide+Carfilzomib (KRd) regimen? | Patients treated with the Dexamethasone+Lenalidomide+Carfilzomib (KRd) have a median Progression-Free Survival (PFS) rate of 26.1 months, with a 95% CI of (23.2, 30.3). | ### Instruction: What is the median PFS rate for patients that have undergone Dexamethasone+Lenalidomide+Carfilzomib (KRd) regimen?
### Response: Patients treated with the Dexamethasone+Lenalidomide+Carfilzomib (KRd) have a median Progression-Free Survival (PFS) rate of 26.1 months, with a 95% CI of (23.2, 30.3). |
Could you tell me the median Progression-Free Survival rate for patients who received Dexamethasone+Lenalidomide+Carfilzomib (KRd) regimen? | Patients treated with the Dexamethasone+Lenalidomide+Carfilzomib (KRd) have a median Progression-Free Survival (PFS) rate of 26.1 months, with a 95% CI of (23.2, 30.3). | ### Instruction: Could you tell me the median Progression-Free Survival rate for patients who received Dexamethasone+Lenalidomide+Carfilzomib (KRd) regimen?
### Response: Patients treated with the Dexamethasone+Lenalidomide+Carfilzomib (KRd) have a median Progression-Free Survival (PFS) rate of 26.1 months, with a 95% CI of (23.2, 30.3). |
What’s the median rate of PFS in patients treated with Dexamethasone+Lenalidomide+Carfilzomib (KRd) regimen? | Patients treated with the Dexamethasone+Lenalidomide+Carfilzomib (KRd) have a median Progression-Free Survival (PFS) rate of 26.1 months, with a 95% CI of (23.2, 30.3). | ### Instruction: What’s the median rate of PFS in patients treated with Dexamethasone+Lenalidomide+Carfilzomib (KRd) regimen?
### Response: Patients treated with the Dexamethasone+Lenalidomide+Carfilzomib (KRd) have a median Progression-Free Survival (PFS) rate of 26.1 months, with a 95% CI of (23.2, 30.3). |
Can you share the median Progression-Free Survival rate in patients who have received Dexamethasone+Lenalidomide+Carfilzomib (KRd) regimen? | Patients treated with the Dexamethasone+Lenalidomide+Carfilzomib (KRd) have a median Progression-Free Survival (PFS) rate of 26.1 months, with a 95% CI of (23.2, 30.3). | ### Instruction: Can you share the median Progression-Free Survival rate in patients who have received Dexamethasone+Lenalidomide+Carfilzomib (KRd) regimen?
### Response: Patients treated with the Dexamethasone+Lenalidomide+Carfilzomib (KRd) have a median Progression-Free Survival (PFS) rate of 26.1 months, with a 95% CI of (23.2, 30.3). |
Can you tell me the median PFS for Lenalidomide+Dexamethasone (Rd)? | Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 16.6 months, with a 95% CI of (14.5, 19.4). | ### Instruction: Can you tell me the median PFS for Lenalidomide+Dexamethasone (Rd)?
### Response: Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 16.6 months, with a 95% CI of (14.5, 19.4). |
What’s the median PFS associated with Lenalidomide+Dexamethasone (Rd)? | Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 16.6 months, with a 95% CI of (14.5, 19.4). | ### Instruction: What’s the median PFS associated with Lenalidomide+Dexamethasone (Rd)?
### Response: Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 16.6 months, with a 95% CI of (14.5, 19.4). |
Could you provide the median PFS of Lenalidomide+Dexamethasone (Rd)? | Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 16.6 months, with a 95% CI of (14.5, 19.4). | ### Instruction: Could you provide the median PFS of Lenalidomide+Dexamethasone (Rd)?
### Response: Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 16.6 months, with a 95% CI of (14.5, 19.4). |
I’d like to know the median PFS of Lenalidomide+Dexamethasone (Rd). | Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 16.6 months, with a 95% CI of (14.5, 19.4). | ### Instruction: I’d like to know the median PFS of Lenalidomide+Dexamethasone (Rd).
### Response: Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 16.6 months, with a 95% CI of (14.5, 19.4). |
Do you have information on the median PFS of Lenalidomide+Dexamethasone (Rd)? | Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 16.6 months, with a 95% CI of (14.5, 19.4). | ### Instruction: Do you have information on the median PFS of Lenalidomide+Dexamethasone (Rd)?
### Response: Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 16.6 months, with a 95% CI of (14.5, 19.4). |
What is the median progression-free survival (PFS) for Lenalidomide+Dexamethasone (Rd)? | Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 16.6 months, with a 95% CI of (14.5, 19.4). | ### Instruction: What is the median progression-free survival (PFS) for Lenalidomide+Dexamethasone (Rd)?
### Response: Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 16.6 months, with a 95% CI of (14.5, 19.4). |
Can you inform me about the median PFS for Lenalidomide+Dexamethasone (Rd)? | Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 16.6 months, with a 95% CI of (14.5, 19.4). | ### Instruction: Can you inform me about the median PFS for Lenalidomide+Dexamethasone (Rd)?
### Response: Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 16.6 months, with a 95% CI of (14.5, 19.4). |
I’m interested in the median PFS of Lenalidomide+Dexamethasone (Rd). | Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 16.6 months, with a 95% CI of (14.5, 19.4). | ### Instruction: I’m interested in the median PFS of Lenalidomide+Dexamethasone (Rd).
### Response: Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 16.6 months, with a 95% CI of (14.5, 19.4). |
Could you tell me the median PFS for Lenalidomide+Dexamethasone (Rd)? | Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 16.6 months, with a 95% CI of (14.5, 19.4). | ### Instruction: Could you tell me the median PFS for Lenalidomide+Dexamethasone (Rd)?
### Response: Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 16.6 months, with a 95% CI of (14.5, 19.4). |
What is the median PFS rate for Lenalidomide+Dexamethasone (Rd)? | Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 16.6 months, with a 95% CI of (14.5, 19.4). | ### Instruction: What is the median PFS rate for Lenalidomide+Dexamethasone (Rd)?
### Response: Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 16.6 months, with a 95% CI of (14.5, 19.4). |
What is the median Progression-Free Survival (PFS) rate in patients treated with Lenalidomide+Dexamethasone (Rd) regimen? | Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 16.6 months, with a 95% CI of (14.5, 19.4). | ### Instruction: What is the median Progression-Free Survival (PFS) rate in patients treated with Lenalidomide+Dexamethasone (Rd) regimen?
### Response: Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 16.6 months, with a 95% CI of (14.5, 19.4). |
What is the median PFS rate in patients who have undergone Lenalidomide+Dexamethasone (Rd) regimen? | Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 16.6 months, with a 95% CI of (14.5, 19.4). | ### Instruction: What is the median PFS rate in patients who have undergone Lenalidomide+Dexamethasone (Rd) regimen?
### Response: Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 16.6 months, with a 95% CI of (14.5, 19.4). |
Can you tell me the median Progression-Free Survival rate in patients who were treated with Lenalidomide+Dexamethasone (Rd) regimen? | Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 16.6 months, with a 95% CI of (14.5, 19.4). | ### Instruction: Can you tell me the median Progression-Free Survival rate in patients who were treated with Lenalidomide+Dexamethasone (Rd) regimen?
### Response: Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 16.6 months, with a 95% CI of (14.5, 19.4). |
What’s the median PFS rate for patients receiving Lenalidomide+Dexamethasone (Rd) regimen? | Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 16.6 months, with a 95% CI of (14.5, 19.4). | ### Instruction: What’s the median PFS rate for patients receiving Lenalidomide+Dexamethasone (Rd) regimen?
### Response: Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 16.6 months, with a 95% CI of (14.5, 19.4). |
Could you provide the median Progression-Free Survival rate for patients treated with Lenalidomide+Dexamethasone (Rd) regimen? | Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 16.6 months, with a 95% CI of (14.5, 19.4). | ### Instruction: Could you provide the median Progression-Free Survival rate for patients treated with Lenalidomide+Dexamethasone (Rd) regimen?
### Response: Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 16.6 months, with a 95% CI of (14.5, 19.4). |
What is the median rate of Progression-Free Survival in patients who have been treated with Lenalidomide+Dexamethasone (Rd) regimen? | Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 16.6 months, with a 95% CI of (14.5, 19.4). | ### Instruction: What is the median rate of Progression-Free Survival in patients who have been treated with Lenalidomide+Dexamethasone (Rd) regimen?
### Response: Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 16.6 months, with a 95% CI of (14.5, 19.4). |
Can you inform me about the median PFS rate in patients that were treated with Lenalidomide+Dexamethasone (Rd) regimen? | Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 16.6 months, with a 95% CI of (14.5, 19.4). | ### Instruction: Can you inform me about the median PFS rate in patients that were treated with Lenalidomide+Dexamethasone (Rd) regimen?
### Response: Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 16.6 months, with a 95% CI of (14.5, 19.4). |
What is the median PFS rate for patients that have undergone Lenalidomide+Dexamethasone (Rd) regimen? | Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 16.6 months, with a 95% CI of (14.5, 19.4). | ### Instruction: What is the median PFS rate for patients that have undergone Lenalidomide+Dexamethasone (Rd) regimen?
### Response: Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 16.6 months, with a 95% CI of (14.5, 19.4). |
Could you tell me the median Progression-Free Survival rate for patients who received Lenalidomide+Dexamethasone (Rd) regimen? | Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 16.6 months, with a 95% CI of (14.5, 19.4). | ### Instruction: Could you tell me the median Progression-Free Survival rate for patients who received Lenalidomide+Dexamethasone (Rd) regimen?
### Response: Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 16.6 months, with a 95% CI of (14.5, 19.4). |
What’s the median rate of PFS in patients treated with Lenalidomide+Dexamethasone (Rd) regimen? | Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 16.6 months, with a 95% CI of (14.5, 19.4). | ### Instruction: What’s the median rate of PFS in patients treated with Lenalidomide+Dexamethasone (Rd) regimen?
### Response: Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 16.6 months, with a 95% CI of (14.5, 19.4). |
Can you share the median Progression-Free Survival rate in patients who have received Lenalidomide+Dexamethasone (Rd) regimen? | Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 16.6 months, with a 95% CI of (14.5, 19.4). | ### Instruction: Can you share the median Progression-Free Survival rate in patients who have received Lenalidomide+Dexamethasone (Rd) regimen?
### Response: Patients treated with the Lenalidomide+Dexamethasone (Rd) have a median Progression-Free Survival (PFS) rate of 16.6 months, with a 95% CI of (14.5, 19.4). |
Can you tell me the median PFS for Lenalidomide+Dexamethasone+Elotuzumab (ERd)? | Patients treated with the Lenalidomide+Dexamethasone+Elotuzumab (ERd) have a median Progression-Free Survival (PFS) rate of 19.4 months, with a 95% CI of (16.6, 22.2). | ### Instruction: Can you tell me the median PFS for Lenalidomide+Dexamethasone+Elotuzumab (ERd)?
### Response: Patients treated with the Lenalidomide+Dexamethasone+Elotuzumab (ERd) have a median Progression-Free Survival (PFS) rate of 19.4 months, with a 95% CI of (16.6, 22.2). |
What’s the median PFS associated with Lenalidomide+Dexamethasone+Elotuzumab (ERd)? | Patients treated with the Lenalidomide+Dexamethasone+Elotuzumab (ERd) have a median Progression-Free Survival (PFS) rate of 19.4 months, with a 95% CI of (16.6, 22.2). | ### Instruction: What’s the median PFS associated with Lenalidomide+Dexamethasone+Elotuzumab (ERd)?
### Response: Patients treated with the Lenalidomide+Dexamethasone+Elotuzumab (ERd) have a median Progression-Free Survival (PFS) rate of 19.4 months, with a 95% CI of (16.6, 22.2). |
Could you provide the median PFS of Lenalidomide+Dexamethasone+Elotuzumab (ERd)? | Patients treated with the Lenalidomide+Dexamethasone+Elotuzumab (ERd) have a median Progression-Free Survival (PFS) rate of 19.4 months, with a 95% CI of (16.6, 22.2). | ### Instruction: Could you provide the median PFS of Lenalidomide+Dexamethasone+Elotuzumab (ERd)?
### Response: Patients treated with the Lenalidomide+Dexamethasone+Elotuzumab (ERd) have a median Progression-Free Survival (PFS) rate of 19.4 months, with a 95% CI of (16.6, 22.2). |
I’d like to know the median PFS of Lenalidomide+Dexamethasone+Elotuzumab (ERd). | Patients treated with the Lenalidomide+Dexamethasone+Elotuzumab (ERd) have a median Progression-Free Survival (PFS) rate of 19.4 months, with a 95% CI of (16.6, 22.2). | ### Instruction: I’d like to know the median PFS of Lenalidomide+Dexamethasone+Elotuzumab (ERd).
### Response: Patients treated with the Lenalidomide+Dexamethasone+Elotuzumab (ERd) have a median Progression-Free Survival (PFS) rate of 19.4 months, with a 95% CI of (16.6, 22.2). |
Do you have information on the median PFS of Lenalidomide+Dexamethasone+Elotuzumab (ERd)? | Patients treated with the Lenalidomide+Dexamethasone+Elotuzumab (ERd) have a median Progression-Free Survival (PFS) rate of 19.4 months, with a 95% CI of (16.6, 22.2). | ### Instruction: Do you have information on the median PFS of Lenalidomide+Dexamethasone+Elotuzumab (ERd)?
### Response: Patients treated with the Lenalidomide+Dexamethasone+Elotuzumab (ERd) have a median Progression-Free Survival (PFS) rate of 19.4 months, with a 95% CI of (16.6, 22.2). |
What is the median progression-free survival (PFS) for Lenalidomide+Dexamethasone+Elotuzumab (ERd)? | Patients treated with the Lenalidomide+Dexamethasone+Elotuzumab (ERd) have a median Progression-Free Survival (PFS) rate of 19.4 months, with a 95% CI of (16.6, 22.2). | ### Instruction: What is the median progression-free survival (PFS) for Lenalidomide+Dexamethasone+Elotuzumab (ERd)?
### Response: Patients treated with the Lenalidomide+Dexamethasone+Elotuzumab (ERd) have a median Progression-Free Survival (PFS) rate of 19.4 months, with a 95% CI of (16.6, 22.2). |
Can you inform me about the median PFS for Lenalidomide+Dexamethasone+Elotuzumab (ERd)? | Patients treated with the Lenalidomide+Dexamethasone+Elotuzumab (ERd) have a median Progression-Free Survival (PFS) rate of 19.4 months, with a 95% CI of (16.6, 22.2). | ### Instruction: Can you inform me about the median PFS for Lenalidomide+Dexamethasone+Elotuzumab (ERd)?
### Response: Patients treated with the Lenalidomide+Dexamethasone+Elotuzumab (ERd) have a median Progression-Free Survival (PFS) rate of 19.4 months, with a 95% CI of (16.6, 22.2). |
I’m interested in the median PFS of Lenalidomide+Dexamethasone+Elotuzumab (ERd). | Patients treated with the Lenalidomide+Dexamethasone+Elotuzumab (ERd) have a median Progression-Free Survival (PFS) rate of 19.4 months, with a 95% CI of (16.6, 22.2). | ### Instruction: I’m interested in the median PFS of Lenalidomide+Dexamethasone+Elotuzumab (ERd).
### Response: Patients treated with the Lenalidomide+Dexamethasone+Elotuzumab (ERd) have a median Progression-Free Survival (PFS) rate of 19.4 months, with a 95% CI of (16.6, 22.2). |
Could you tell me the median PFS for Lenalidomide+Dexamethasone+Elotuzumab (ERd)? | Patients treated with the Lenalidomide+Dexamethasone+Elotuzumab (ERd) have a median Progression-Free Survival (PFS) rate of 19.4 months, with a 95% CI of (16.6, 22.2). | ### Instruction: Could you tell me the median PFS for Lenalidomide+Dexamethasone+Elotuzumab (ERd)?
### Response: Patients treated with the Lenalidomide+Dexamethasone+Elotuzumab (ERd) have a median Progression-Free Survival (PFS) rate of 19.4 months, with a 95% CI of (16.6, 22.2). |
What is the median PFS rate for Lenalidomide+Dexamethasone+Elotuzumab (ERd)? | Patients treated with the Lenalidomide+Dexamethasone+Elotuzumab (ERd) have a median Progression-Free Survival (PFS) rate of 19.4 months, with a 95% CI of (16.6, 22.2). | ### Instruction: What is the median PFS rate for Lenalidomide+Dexamethasone+Elotuzumab (ERd)?
### Response: Patients treated with the Lenalidomide+Dexamethasone+Elotuzumab (ERd) have a median Progression-Free Survival (PFS) rate of 19.4 months, with a 95% CI of (16.6, 22.2). |
What is the median Progression-Free Survival (PFS) rate in patients treated with Lenalidomide+Dexamethasone+Elotuzumab (ERd) regimen? | Patients treated with the Lenalidomide+Dexamethasone+Elotuzumab (ERd) have a median Progression-Free Survival (PFS) rate of 19.4 months, with a 95% CI of (16.6, 22.2). | ### Instruction: What is the median Progression-Free Survival (PFS) rate in patients treated with Lenalidomide+Dexamethasone+Elotuzumab (ERd) regimen?
### Response: Patients treated with the Lenalidomide+Dexamethasone+Elotuzumab (ERd) have a median Progression-Free Survival (PFS) rate of 19.4 months, with a 95% CI of (16.6, 22.2). |
What is the median PFS rate in patients who have undergone Lenalidomide+Dexamethasone+Elotuzumab (ERd) regimen? | Patients treated with the Lenalidomide+Dexamethasone+Elotuzumab (ERd) have a median Progression-Free Survival (PFS) rate of 19.4 months, with a 95% CI of (16.6, 22.2). | ### Instruction: What is the median PFS rate in patients who have undergone Lenalidomide+Dexamethasone+Elotuzumab (ERd) regimen?
### Response: Patients treated with the Lenalidomide+Dexamethasone+Elotuzumab (ERd) have a median Progression-Free Survival (PFS) rate of 19.4 months, with a 95% CI of (16.6, 22.2). |
Can you tell me the median Progression-Free Survival rate in patients who were treated with Lenalidomide+Dexamethasone+Elotuzumab (ERd) regimen? | Patients treated with the Lenalidomide+Dexamethasone+Elotuzumab (ERd) have a median Progression-Free Survival (PFS) rate of 19.4 months, with a 95% CI of (16.6, 22.2). | ### Instruction: Can you tell me the median Progression-Free Survival rate in patients who were treated with Lenalidomide+Dexamethasone+Elotuzumab (ERd) regimen?
### Response: Patients treated with the Lenalidomide+Dexamethasone+Elotuzumab (ERd) have a median Progression-Free Survival (PFS) rate of 19.4 months, with a 95% CI of (16.6, 22.2). |
What’s the median PFS rate for patients receiving Lenalidomide+Dexamethasone+Elotuzumab (ERd) regimen? | Patients treated with the Lenalidomide+Dexamethasone+Elotuzumab (ERd) have a median Progression-Free Survival (PFS) rate of 19.4 months, with a 95% CI of (16.6, 22.2). | ### Instruction: What’s the median PFS rate for patients receiving Lenalidomide+Dexamethasone+Elotuzumab (ERd) regimen?
### Response: Patients treated with the Lenalidomide+Dexamethasone+Elotuzumab (ERd) have a median Progression-Free Survival (PFS) rate of 19.4 months, with a 95% CI of (16.6, 22.2). |
Could you provide the median Progression-Free Survival rate for patients treated with Lenalidomide+Dexamethasone+Elotuzumab (ERd) regimen? | Patients treated with the Lenalidomide+Dexamethasone+Elotuzumab (ERd) have a median Progression-Free Survival (PFS) rate of 19.4 months, with a 95% CI of (16.6, 22.2). | ### Instruction: Could you provide the median Progression-Free Survival rate for patients treated with Lenalidomide+Dexamethasone+Elotuzumab (ERd) regimen?
### Response: Patients treated with the Lenalidomide+Dexamethasone+Elotuzumab (ERd) have a median Progression-Free Survival (PFS) rate of 19.4 months, with a 95% CI of (16.6, 22.2). |
What is the median rate of Progression-Free Survival in patients who have been treated with Lenalidomide+Dexamethasone+Elotuzumab (ERd) regimen? | Patients treated with the Lenalidomide+Dexamethasone+Elotuzumab (ERd) have a median Progression-Free Survival (PFS) rate of 19.4 months, with a 95% CI of (16.6, 22.2). | ### Instruction: What is the median rate of Progression-Free Survival in patients who have been treated with Lenalidomide+Dexamethasone+Elotuzumab (ERd) regimen?
### Response: Patients treated with the Lenalidomide+Dexamethasone+Elotuzumab (ERd) have a median Progression-Free Survival (PFS) rate of 19.4 months, with a 95% CI of (16.6, 22.2). |
End of preview. Expand
in Dataset Viewer.
- Downloads last month
- 0